"Effects of trilaciclib prior to chemotherapy ± atezolizumab on T-cell activation in patients with newly diagnosed extensive-stage small cell lung cancer." by Aaron D. Stevens

Selected Works of Jerome Goldschmidt, MD

Article

Effects of trilaciclib prior to chemotherapy ± atezolizumab on T-cell activation in patients with newly diagnosed extensive-stage small cell lung cancer.

Journal of Clinical Oncology (2021)

Aaron D. Stevens, Research Triangle Park
Davey B. Daniel, Sarah Cannon Research Institute
Jerome H. Goldschmidt, Blue Ridge Cancer Care, Blacksburg, VA;
Paul A. Fields, Adaptive Biotechnologies, Seattle, WA;
Barb Banbury, Adaptive Biotechnologies, Seattle, WA;
Steven Wolfe, Research Triangle Park
Jarrett Glass, Research Triangle Park
Janet K. Horton, Research Triangle Park
Jessica Sorrentino, Research Triangle Park

Link

Disciplines

Publication Date

May 20, 2021

DOI

10.1200/JCO.2021.39.15_SUPPL.E20582

Citation Information

Aaron D. Stevens, Davey B. Daniel, Jerome H. Goldschmidt, Paul A. Fields, et al.. "Effects of trilaciclib prior to chemotherapy ± atezolizumab on T-cell activation in patients with newly diagnosed extensive-stage small cell lung cancer." Journal of Clinical Oncology Vol. 39 (2021)
Available at: http://works.bepress.com/jerome-goldschmidt/4/